BCIQ Profiles

Company Profile Report

Axicabtagene ciloleucel: Additional Ph I/II ZUMA-1 data

Data from 101 patients with chemorefractory aggressive B cell NHL in the open-label, U.S. and Israeli Phase I/II ZUMA-1 trial showed that a single IV infusion of axicabtagene ciloleucel led to an ORR of 82% and a

Read the full 373 word article

How to gain access

Continue reading with a
two-week free trial.